Division of Takeda Pharmaceutical Co. Ltd.
Latest From Cellerix SA
TiGenix' wholly-owned subsidiary, Cellerix, is to receive nearly €5 million in a soft loan from the "Madrid Network" to finance a Phase III fistula programme in Crohn's disease.
Regenerative medicine is widely seen as playing a vital future role in difficult-to-treat conditions like diabetes, Parkinson's disease and stroke. But can it really deliver on its promise, or is it simply being hyped up to persuade investors to put money into what is a young and unpredictable area of research?
Belgian firm TiGenix has agreed to merge with Cellerix, a Spanish company specialising in adipose tissue-derived stem cell therapies, in a bid to gain critical mass in the regenerative medicine market.
- Gene Therapy, Cell Therapy
- Therapeutic Areas
- Immune Disorders
- Musculoskeletal & Connective Tissue Disorders
- Western Europe
- Parent & Subsidiaries
- Takeda Pharmaceutical Co. Ltd.
- Senior Management
Eduardo Bravo, CEO
Claudia D'Augusta, PhD, CFO
Jose Luis Bravo, MD, PhD, VP, Global Medical, R&D
- Contact Info
Phone: (34) 91 804 92 64
Calle Marconi, 1
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.